ERAS-12

N/A

Report date: 2021/12/07 13:29:07

Base Information

Drug NameERAS-12

Drug Alias NameERAS-12

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsEpidermal growth factor receptor variant III antagonists

TargetsEpidermal growth factor receptor erbB1Epidermal growth factor receptor variant III

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesErasca Inc

China Registration ClassN/A

Develop Information

Active CompaniesErasca Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A